CenTrial Logo

Is Normal Saline Effective in Preventing Kidney Damage in G6PDd?


Clinical trial finds no difference in saline solution effectiveness.

Are you a parent of a child with glucose 6 phosphate dehydrogenase (G6PD) deficiency? Are you worried about the potential risks associated with acute kidney injury (AKI) and unsure of the best fluid therapy method to prevent it? This clinical trial may contain important information.

Glucose 6 phosphate dehydrogenase deficiency (G6PDd) is the most common enzyme deficiency in humans. G6PD deficiency is a genetic condition that affects red blood cells and can lead to anemia and other complications. Heme-induced nephropathy (HIN) is a rare but serious complication that can occur when patients with G6PD deficiency receive intravenous heme-containing products, such as blood transfusions or certain medications.

HIN can lead to acute kidney injury and potentially permanent damage. There are several fluid therapies available to prevent acute kidney injury in G6PDd patients. However, strong clinical trials demonstrating their safety and effectiveness are lacking.

Clinical Trial

A clinical trial explores the safety and effectiveness of normal saline fluid therapy for preventing hemolysis-related acute kidney injury in children with glucose 6 phosphate dehydrogenase (G6PD) deficiency.

The trial assessed the effectiveness of normal saline, a commonly used but least-examined fluid therapy method, in preventing HIN in children with G6PD deficiency.

It included 120 children with G6PD deficiency who were suffering from acute hemolysis. The children were randomly assigned to receive either normal saline, normal saline with sodium bicarbonate, or normal saline with acetazolamide. The frequency of AKI in these patients was measured.

Are you interested in clinical trials near you?

You can receive free notification of a trial for this, or any other condition, by completing a short confidential health profile.
Find a clinical trial near me


The results of the clinical trial showed that normal saline alone, normal saline with sodium bicarbonate, and normal saline acetazolamide were equally effective in preventing HIN, with no significant difference between the three groups. Out of the 120 patients in the clinical trial, AKI occurred in only 1 patient receiving normal saline and sodium bicarbonate.

The trial has important implications for clinicians who care for children with G6PD deficiency and need to make decisions about fluid therapy methods to prevent HIN. Normal saline alone may be a viable alternative to sodium bicarbonate and acetazolamide taken in combination with saline, especially in resource-limited settings where cost and availability may be a concern.


The clinical trial provides important new evidence about the effectiveness and safety of normal saline as a sole fluid therapy method for preventing HIN in children with G6PD deficiency. If you have concerns about your child's risk of HIN and the best way to prevent it, be sure to talk to your child's healthcare provider.

Share this article with a friend:

Get emailed clinical trial results in the categories of your choice:
Free subscription to clinical trial results

Signup to be notified of clinical trials near you that match your condition

Signup and be matched to trials near you
This free service will notify you of current and future clinical trial matches.

This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. CenTrial Data Ltd. does not take responsibility for possible health consequences of any person or persons reading or following the information in this educational content. Treatments and clinical trials mentioned may not be appropriate or available for all trial participants. Outcomes from treatments and clinical trials may vary from person to person. Consult with your doctor as to whether a clinical trial is a suitable option for your condition. Assistance from generative AI tools may have been used in writing this article.